Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunourchin is navigating the prosecution of 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner, which centralizes the company's legal interactions at the USPTO. Such a pipeline suggests a specific focus for the company's current patenting efforts.
The prosecution is localized within 1 distinct art unit, indicating that the subject matter falls under a specific technical category. ABBAS, SYED JARAR is the busiest examiner for the company, currently managing 1 pending office action. This examiner is responsible for the active workload of the portfolio, creating a link between the applicant and a specific reviewer.
For a practitioner, this structure means that the success of the current prosecution depends on the feedback from ABBAS, SYED JARAR. The absence of multiple examiners simplifies the strategy, as there is no need to reconcile different examination styles. Instead, the focus remains on the 1 pending office action and the requirements of the assigned examiner within that 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247252 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | ABBAS, SYED JARAR | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18247252 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | ABBAS, SYED JARAR | 1674 | §112 | Non-Final OA | — | Pending | Mar 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunourchin has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Syed Jarar Abbas has the most, with 1 of Immunourchin's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
